Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: Rationale & design of the ARCHER trial.
Anti‐inflammatory
CMR
Cannabidiol
Myocarditis
Randomized trial
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
27 Jun 2024
27 Jun 2024
Historique:
revised:
10
05
2024
received:
10
04
2024
accepted:
11
05
2024
medline:
28
6
2024
pubmed:
28
6
2024
entrez:
28
6
2024
Statut:
aheadofprint
Résumé
Acute myocarditis, although a rare disease, can be associated with sudden cardiac death or the need for transplantation in both children and young adults. To date, there is no definitive evidence to support the routine use of immunosuppressive therapy or treatment targeting inflammation in patients with myocarditis. Animal models of cardiovascular (CV), as well as neurological diseases, have demonstrated that cannabidiol has significant anti-inflammatory properties and may represent a promising therapy in acute myocarditis. This efficacy has been shown in a murine model of autoimmune myocarditis as well as in in vitro and in vivo models of heart failure (HF). We present the rationale and design of the ARCHER Trial, an international multicentre, double-blind, randomized, placebo-controlled, phase II study examining the safety and efficacy of a pharmaceutically produced cannabidiol formulation, in patients with mild to moderate acute myocarditis. Eligible patients are those with acute myocarditis, randomized within 10 days of the diagnostic cardiac MRI (CMR), which has met defined diagnostic criteria for myocarditis. Oral treatment (cannabidiol or placebo) is titrated from 2.5 mg/kg of body weight up to 10 mg/kg of body weight b.i.d. (or highest tolerated dose) and taken for 12 weeks in addition to standard of care therapy for HF. The primary endpoints are defined as changes in global longitudinal strain (GLS) and extra cellular volume (ECV), measured by CMR at 12 weeks. Assuming 80% power, a 5% alpha risk and 25% missing CMR follow-up data at Week 12, 100 patients are required to demonstrate the desired treatment effect of 18%. The change in left ventricular ejection fraction (LVEF) from baseline to Week 12 was selected as the secondary endpoint. Additional exploratory endpoints include changes in hs-troponin, NT-proBNP, markers of inflammation and endothelial function during the 12-week treatment period. The trial is ongoing but is now more than 50% recruited. As enrolment in the trial continues, no interim data are available for inclusion in this Design paper. The ongoing ARCHER Trial is an international, multicentre, double-blind, randomized, placebo-controlled phase II study, designed to determine the effect of a pharmaceutically produced cannabidiol formulation on CMR parameters in patients presenting with acute myocarditis. Enrolment of 100 patients is expected to conclude in Q3 2024. Study results will be available in early 2025.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cardiol Therapeutics Inc., Canada
Informations de copyright
© 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Tschöpe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol 2020;12:169‐193. doi:10.1038/s41569‐020‐00435‐x
Matsumori A, Furukawa Y, Hasegawa K, Sato Y, Nakagawa H, Morikawa Y, et al. Epidemiologic and clinical characteristics of cardiomyopathies in Japan: results from nationwide surveys. Circ J Off J Jpn Circ Soc 2002;66:323‐336. doi:10.1253/circj.66.323
Fairweather D, Beetler DJ, Di Florio DN, Musigk N, Heidecker B, Cooper LT. COVID‐19, myocarditis and pericarditis. Circ Res 2023;132:1302‐1319. doi:10.1161/CIRCRESAHA.123.321878
Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018;71:1755‐1764. doi:10.1016/j.jacc.2018.02.037
Sagar S, Liu PP, Cooper LT. Myocarditis. Lancet Lond Engl 2012;379:738‐747. doi:10.1016/S0140‐6736(11)60648‐X
Tschöpe C, Cooper LT, Torre‐Amione G, Van Linthout S. Management of myocarditis‐related cardiomyopathy in adults. Circ Res 2019;124:1568‐1583. doi:10.1161/CIRCRESAHA.118.313578
Ammirati E, Cipriani M, Lilliu M, Sormani P, Varrenti M, Raineri C, et al. Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis. Circulation 2017;136:529‐545. doi:10.1161/CIRCULATIONAHA.117.026386
Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus‐negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009;30:1995‐2002. doi:10.1093/eurheartj/ehp249
Chimenti C, Russo MA, Frustaci A. Immunosuppressive therapy in virus‐negative inflammatory cardiomyopathy: 20‐year follow‐up of the TIMIC trial. Eur Heart J 2022;43:3463‐3473. doi:10.1093/eurheartj/ehac348
Merken J, Hazebroek M, Van Paassen P, et al. Immunosuppressive therapy improves both short‐ and long‐term prognosis in patients with virus‐negative nonfulminant inflammatory cardiomyopathy. Circ Heart Fail 2018;11:e004228. doi:10.1161/CIRCHEARTFAILURE.117.004228
Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, et al. A clinical trial of immunosuppressive therapy for myocarditis. The myocarditis treatment trial investigators. N Engl J Med 1995;333:269‐275. doi:10.1056/NEJM199508033330501
Kühl U, Pauschinger M, Schwimmbeck PL, et al. Interferon‐beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003;107:2793‐2798. doi:10.1161/01.CIR.0000072766.67150.51
Kühl U, Lassner D, von Schlippenbach J, Poller W, Schultheiss HP. Interferon‐Beta improves survival in enterovirus‐associated cardiomyopathy. J Am Coll Cardiol 2012;60:1295‐1296. doi:10.1016/j.jacc.2012.06.026
McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent‐onset dilated cardiomyopathy. Circulation 2001;103:2254‐2259. doi:10.1161/01.cir.103.18.2254
Kerneis M, Cohen F, Combes A, Vicaut E, Montalescot G. The ARAMIS trial. Anakinra versus placebo, a double blind randomized controlled trial for the treatment of acute myocarditis. Presented at: ESC Congress; Amsterdam, 2023.
Martinez Naya N, Nirar AH, Kim MM, et al. Protective effects of cannabidiol in a mouse model of acute pericarditis. Circ Res 2022;131:e169‐e190. doi:10.1161/RES.0000000000000584
Martinez Naya N, Kelly J, Corna G, Golino M, Polizio AH, Abbate A, et al. An overview of cannabidiol as a multifunctional drug: pharmacokinetics and cellular effects. Mol Basel Switz 2024;29:473. doi:10.3390/molecules29020473
Isaak A, Kravchenko D, Mesropyan N, Endler C, Bischoff LM, Vollbrecht T, et al. Layer‐specific strain analysis with cardiac MRI feature tracking in acute myocarditis. Radiol Cardiothorac Imaging 2022;4:e210318. doi:10.1148/ryct.210318
Benjamini Y, Hochberg Y. Controlling the false discovery rate:a practical and powerful approach to multiple testing. J R Stat Soc 1995;57:289‐300.
Rajesh M, Mukhopadhyay P, Bátkai S, Patel V, Saito K, Matsumoto S, et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 2010;56:2115‐2125. doi:10.1016/j.jacc.2010.07.033
Fouad AA, Albuali WH, Al‐Mulhim AS, Jresat I. Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity. Environ Toxicol Pharmacol 2013;36:347‐357. doi:10.1016/j.etap.2013.04.018
Hao E, Mukhopadhyay P, Cao Z, Erdélyi K, Holovac E, Liaudet L, et al. Cannabidiol protects against doxorubicin‐induced cardiomyopathy by modulating mitochondrial function and biogenesis. Mol Med 2015;21:38‐45. doi:10.2119/molmed.2014.00261
Lee WS, Erdelyi K, Matyas C, Mukhopadhyay P, Varga ZV, Liaudet L, et al. Cannabidiol limits T cell‐mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation. Mol Med 2016;22:136‐146. doi:10.2119/molmed.2016.00007
Cordero‐Reyes AM, Youker KA, Trevino AR, Celis R, Hamilton DJ, Flores‐Arredondo JH, et al. Full expression of cardiomyopathy is partly dependent on B‐cells: a pathway that involves cytokine activation, immunoglobulin deposition, and activation of apoptosis. J Am Heart Assoc Cardiovasc Cerebrovasc Dis 2016;5: doi:10.1161/JAHA.115.002484
Brown AJ. Novel cannabinoid receptors. Br J Pharmacol 2007;152:567‐575. doi:10.1038/sj.bjp.0707481
Laun AS, Song ZH. GPR3 and GPR6, novel molecular targets for cannabidiol. Biochem Biophys Res Commun 2017;490:17‐21. doi:10.1016/j.bbrc.2017.05.165
Morales P, Reggio PH. An update on non‐CB1, non‐CB2 cannabinoid related G‐protein‐coupled receptors. Cannabis Cannabinoid Res 2017;2:265‐273. doi:10.1089/can.2017.0036
Martinez Naya N, Kelly J, Corna G, Golino M, Abbate A, Toldo S. Molecular and cellular mechanisms of action of cannabidiol. Mol Basel Switz 2023;28:5980. doi:10.3390/molecules28165980
Toldo S, Mezzaroma E, Buckley LF, Potere N, di Nisio M, Biondi‐Zoccai G, et al. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacol Ther 2022;236:108053. doi:10.1016/j.pharmthera.2021.108053
Toldo S, Abbate A. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases. Nat Rev Cardiol 2024;21:219‐237. doi:10.1038/s41569‐023‐00946‐3
Chu FX, Wang X, Li B, Xu LL, Di B. The NLRP3 inflammasome: a vital player in inflammation and mediating the anti‐inflammatory effect of CBD. Inflamm Res Off J Eur Histamine Res Soc Al 2024;73:227‐242. doi:10.1007/s00011‐023‐01831‐y
Cavalli G, Pappalardo F, Mangieri A, Dinarello CA, Dagna L, Tresoldi M. Treating life‐threatening myocarditis by blocking Interleukin‐1. Crit Care Med 2016;44:e751‐e754. doi:10.1097/CCM.0000000000001654
Cikes M, Solomon SD. Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure. Eur Heart J 2016;37:1642‐1650. doi:10.1093/eurheartj/ehv510
André F, Stock FT, Riffel J, Giannitsis E, Steen H, Scharhag J, et al. Incremental value of cardiac deformation analysis in acute myocarditis: a cardiovascular magnetic resonance imaging study. Int J Cardiovasc Imaging 2016;32:1093‐1101. doi:10.1007/s10554‐016‐0878‐0
Hsiao JF, Koshino Y, Bonnichsen CR, Yu Y, Miller FA Jr, Pellikka PA, et al. Speckle tracking echocardiography in acute myocarditis. Int J Cardiovasc Imaging 2013;29:275‐284. doi:10.1007/s10554‐012‐0085‐6
Taylor RJ, Moody WE, Umar F, Edwards NC, Taylor TJ, Stegemann B, et al. Myocardial strain measurement with feature‐tracking cardiovascular magnetic resonance: normal values. Eur Heart J Cardiovasc Imaging 2015;16:871‐881. doi:10.1093/ehjci/jev006
Andre F, Steen H, Matheis P, Westkott M, Breuninger K, Sander Y, et al. Age‐ and gender‐related normal left ventricular deformation assessed by cardiovascular magnetic resonance feature tracking. J Cardiovasc Magn Reson 2015;17:25. doi:10.1186/s12968‐015‐0123‐3
Radunski UK, Lund GK, Säring D, Bohnen S, Stehning C, Schnackenburg B, et al. T1 and T2 mapping cardiovascular magnetic resonance imaging techniques reveal unapparent myocardial injury in patients with myocarditis. Clin Res Cardiol 2017;106:10‐17. doi:10.1007/s00392‐016‐1018‐5
Gräni C, Bière L, Eichhorn C, Kaneko K, Agarwal V, Aghayev A, et al. Incremental value of extracellular volume assessment by cardiovascular magnetic resonance imaging in risk stratifying patients with suspected myocarditis. Int J Cardiovasc Imaging 2019;35:1067‐1078. doi:10.1007/s10554‐019‐01552‐6
Fischer K, Obrist SJ, Erne SA, Stark AW, Marggraf M, Kaneko K, et al. Feature tracking myocardial strain incrementally improves prognostication in myocarditis beyond traditional CMR imaging features. JACC Cardiovasc Imaging 2020;13:1891‐1901. doi:10.1016/j.jcmg.2020.04.025
Soeiro AM, Bossa AS, César MC, Leal TCAT, Garcia G, Fonseca RA, et al. The association of myocardial strain with cardiac magnetic resonance and clinical outcomes in patients with acute myocarditis. Front Cardiovasc Med 2023;10:1121083. doi:10.3389/fcvm.2023.1121083
Berg J, Kottwitz J, Baltensperger N, Kissel CK, Lovrinovic M, Mehra T, et al. Cardiac magnetic resonance imaging in myocarditis reveals persistent disease activity despite normalization of cardiac enzymes and inflammatory parameters at 3‐month follow‐up. Circ Heart Fail 2017;10:e004262. doi:10.1161/CIRCHEARTFAILURE.117.004262